No Data
No Data
Shanghai Hile Bio-Technology (603718.SH): planning to adjust the subscription of shares in the Shanghai Runling M&A Fund.
On December 23, Gelonghui reported that Shanghai Hile Bio-Technology (603718.SH) announced that the company recently received a change notice from Wuxi Haoling Investment Management Partnership (Limited Partnership) (referred to as "Wuxi Haoling"), the general partner, executive managing partner, and fund manager of the Shanghai Runling M&A Fund. The total subscribed capital contribution of the Shanghai Runling M&A Fund is planned to be adjusted from 650 million RMB to 122.7 million RMB. Given that the Shanghai Runling M&A Fund is now entering the exit period, the changes are based on fluctuations in policies and regulations, market environment, industry cycles, and other factors, and according to the partnership agreement section 3.3.7.
Retail Investors Invested in Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718) Copped the Brunt of Last Week's CN¥408m Market Cap Decline
Shanghai hile bio-technology (603718.SH): intends to transfer 76.07% equity of Yangling Jinhai to Shanghai Haoyuan.
GrillOn November 11th, Shanghai Hile Bio-Technology (603718.SH) announced that the company held its fifth board of directors meeting on November 11, 2024, and approved the "Proposal on the Sale of Equity of Controlled Subsidiary and Related Transactions", intending to transfer 76.07% equity of Yangling Jinhai held by the company to Shanghai Haoyuan. Considering that the audited book value of the shareholders' equity of Yangling Jinhai as of August 31, 2024 was -201.6444 million yuan, and the assessed valuation of the shareholders' equity was -34.6196 million yuan, the equity transfer price for this transaction is
Risks To Shareholder Returns Are Elevated At These Prices For Shanghai Hile Bio-Technology Co., Ltd. (SHSE:603718)
Hailey Biotech: Hailey Biotech Report for the Third Quarter of 2024
Hailey Biotech 2024 Third Quarter Report
More Unpleasant Surprises Could Be In Store For Shanghai Hile Bio-Technology Co., Ltd.'s (SHSE:603718) Shares After Tumbling 31%
